Nonsteroidal Anti-inflammatory Drugs Alter the Microbiota and Exacerbate Clostridium difficile Colitis while Dysregulating the Inflammatory Response

Damián Maseda, Joseph P. Zackular, Bruno Caetano Trindade, Leslie Kirk, Jennifer Lising Roxas, Lisa M. Rogers, M. Kay Washington, Liping Du, Tatsuki Koyama, V. K. Viswanathan, Gayatri Vedantam, Patrick D. Schloss, Leslie J. Crofford, Eric P. Skaar, David M. Aronoff

This study, published in bioRxiv, explores the dangerous synergy between common painkillers and a notorious hospital-acquired pathogen.

TL;DR

Common nonsteroidal anti-inflammatory drugs (NSAIDs) like indomethacin significantly increase the lethality of Clostridium difficile infections by "unzipping" the intestinal barrier and altering the gut microbiome. This creates a hyper-inflammatory state that allows bacteria to escape the gut and enter the bloodstream, turning a localized infection into a systemic threat.

What Problem Does This Paper Address?

Clostridium difficile infection (CDI) is a leading cause of hospital-acquired diarrhea and can be fatal, particularly in older adults. While antibiotic use is the most well-known risk factor, epidemiological data has long suggested a link between NSAID use and increased CDI severity.

However, the "why" remained a mystery. NSAIDs work by inhibiting cyclooxygenase (COX) enzymes to reduce prostaglandins (PGs)—molecules that signal pain but also help maintain the gut lining. The researchers sought to determine if NSAIDs exacerbate CDI by disrupting the gut's microbial community, weakening the physical intestinal wall, or dysregulating the immune system’s response to the pathogen.

Methods

The authors used a mouse model of antibiotic-associated CDI.

  • The "Perfect Storm" Setup: Mice were given the antibiotic cefoperazone to make them susceptible to C. diff.
  • NSAID Intervention: A subset of mice received a short (two-day) course of indomethacin prior to infection.
  • Multi-omic Analysis: The team employed 16S rRNA gene sequencing to track changes in the microbiota, flow cytometry to identify infiltrating immune cells, and transcriptomics (qRT-PCR and NanoString) to monitor gene expression.
  • Structural Imaging: Transmission electron microscopy (TEM) and immunofluorescence were used to visualize the "tight junctions"—the cellular glue that keeps the gut barrier intact.

Datasets

The study generated and analyzed several experimental datasets:

  • Microbiota Profiles: 16S rRNA sequences (deposited in the NCBI Sequence Read Archive, SRP152292) comparing baseline, antibiotic-treated, and NSAID-treated microbial communities.
  • Transcriptomic Data: Gene expression profiles of cecal tissue focusing on inflammatory pathways and prostaglandin metabolism.
  • Protein Multiplex Data: Concentrations of a panel of inflammatory cytokines and chemokines in gut tissue.

Key Insights and Ideas

  • The Microbiota Shift: Even without infection, indomethacin alone significantly altered the gut's microbial structure. It favored an enrichment of Bacteroides and Akkermansia while decreasing Turicibacter (a genus often associated with a healthy gut).
  • "Unzipping" the Barrier: One of the most striking findings was that the combination of C. diff and NSAIDs caused a physical separation of intestinal epithelial cells. The researchers observed a redistribution of structural proteins (Occludin and ZO-1) from the cell junctions into the cytoplasm, effectively "unzipping" the gut wall.
  • The PGE2 Paradox: While NSAIDs are meant to block prostaglandins, the researchers found a paradoxical increase in PGE2 levels 72 hours post-infection in NSAID-treated mice. This suggests a late-stage dysregulation of the inflammatory response that may actually contribute to tissue damage rather than healing.
  • Immune Overdrive: Rather than suppressing the immune system, NSAIDs appeared to kick it into a damaging overdrive, specifically increasing the recruitment of neutrophils and Th17 cells to the gut.

Key Results

  • Mortality Spike: Pre-exposure to indomethacin increased the mortality rate of CDI from 20% to 80%.
  • Systemic Leakage: NSAID-treated mice showed significantly higher loads of aerobic and anaerobic bacteria in their livers, confirming that the intestinal barrier had been compromised (bacterial translocation).
  • Inflammatory Milieu: There was a massive upregulation of pro-inflammatory markers, including IL-1β, IL-6, and CXCL1, in the ceca of mice treated with both NSAIDs and C. diff.
  • Microbial Signature: Indomethacin-mediated changes in the microbiota persisted for up to 11 days, suggesting that even brief NSAID use has long-lasting effects on gut ecology.

Limitations and Future Work

The authors acknowledge that while indomethacin is a potent NSAID, it is not as commonly used as ibuprofen or aspirin; future studies should investigate if these more common over-the-counter drugs produce the same effects. Additionally, the study uses a mouse model; while the biological pathways are similar, human clinical trials or retrospective cohort studies are needed to confirm these mechanisms in patients.

The researchers suggest that the "unzipping" of the gut barrier might be a generalized mechanism for how various drugs exacerbate intestinal infections, opening a new door for research into drug-microbiota-host interactions.

Summary updated

Abstract

<i>Clostridium difficile</i> infection (CDI) is a major public health threat worldwide. The use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with enhanced susceptibility to and severity of CDI; however, the mechanisms driving this phenomenon have not been elucidated. NSAIDs alter prostaglandin (PG) metabolism by inhibiting cyclooxygenase (COX) enzymes. Here, we found that treatment with the NSAID indomethacin prior to infection altered the microbiota and dramatically increased mortality and the intestinal pathology associated with CDI in mice. We demonstrated that in <i>C. difficile</i>-infected animals, indomethacin treatment led to PG deregulation, an altered proinflammatory transcriptional and protein profile, and perturbed epithelial cell junctions. These effects were paralleled by increased recruitment of intestinal neutrophils and CD4<sup>+</sup> cells and also by a perturbation of the gut microbiota. Together, these data implicate NSAIDs in the disruption of protective COX-mediated PG production during CDI, resulting in altered epithelial integrity and associated immune responses.<b>IMPORTANCE</b><i>Clostridium difficile</i> infection (CDI) is a spore-forming anaerobic bacterium and leading cause of antibiotic-associated colitis. Epidemiological data suggest that use of nonsteroidal anti-inflammatory drugs (NSAIDs) increases the risk for CDI in humans, a potentially important observation given the widespread use of NSAIDs. Prior studies in rodent models of CDI found that NSAID exposure following infection increases the severity of CDI, but mechanisms to explain this are lacking. Here we present new data from a mouse model of antibiotic-associated CDI suggesting that brief NSAID exposure prior to CDI increases the severity of the infectious colitis. These data shed new light on potential mechanisms linking NSAID use to worsened CDI, including drug-induced disturbances to the gut microbiome and colonic epithelial integrity. Studies were limited to a single NSAID (indomethacin), so future studies are needed to assess the generalizability of our findings and to establish a direct link to the human condition.
BibTeX
@inproceedings{maseda2019nonsteroidal,
  author = {Damián Maseda and Joseph P. Zackular and Bruno Caetano Trindade and Leslie Kirk and Jennifer Lising Roxas and Lisa M. Rogers and M. Kay Washington and Liping Du and Tatsuki Koyama and V. K. Viswanathan and Gayatri Vedantam and Patrick D. Schloss and Leslie J. Crofford and Eric P. Skaar and David M. Aronoff},
  title = {{Nonsteroidal Anti-inflammatory Drugs Alter the Microbiota and Exacerbate <i>Clostridium difficile</i> Colitis while Dysregulating the Inflammatory Response}},
  booktitle = {mBio},
  year = {2019},
  doi = {10.1128/mbio.02282-18},
}
Figure